Suven Pharmaceuticals Q2 Results Live : Suven Pharmaceuticals declared their Q2 results on 12 Nov, 2024, showcasing a robust performance with a topline increase of 11.54% year-over-year. The company's profit saw a modest rise of 3.33% compared to the previous year, marking a positive trend in their financial health.
In comparison to the previous quarter, Suven Pharmaceuticals reported an impressive revenue growth of 11.72% along with a significant profit increase of 35.28%. This indicates a strong momentum in their operations and market presence.
However, the Selling, General & Administrative expenses rose sharply by 13.7% quarter-over-quarter and a staggering 81.51% year-over-year, raising concerns about cost management within the company.
On the operational front, the operating income saw a notable upturn of 30.84% quarter-over-quarter and a modest increase of 1.14% year-over-year, reflecting operational efficiency despite rising expenses.
For Q2, the Earnings Per Share (EPS) stood at ₹3.21, which is an increase of 2.56% year-over-year, indicating a slight improvement in profitability per share for investors.
In terms of stock performance, Suven Pharmaceuticals has experienced a -9.72% return in the last week, however, it boasts an impressive 84.53% return over the last six months and a 66.65% year-to-date return, showcasing strong long-term growth potential.
As of now, Suven Pharmaceuticals holds a market capitalization of ₹30,663.62 Crores with a 52-week high of ₹1,353.95 and a low of ₹558.50, suggesting substantial volatility in its stock price over the past year.
As of 13 Nov, 2024, all analysts covering the company have given a 'Strong Buy' rating, reflecting positive sentiment towards Suven Pharmaceuticals' future performance.
Suven Pharmaceuticals Financials
Period | Q2 | Q1 | Q-o-Q Growth | Q2 | Y-o-Y Growth |
---|---|---|---|---|---|
Total Revenue | 257.72 | 230.69 | +11.72% | 231.05 | +11.54% |
Selling/ General/ Admin Expenses Total | 51.87 | 45.62 | +13.7% | 28.58 | +81.51% |
Depreciation/ Amortization | 16.96 | 13.4 | +26.57% | 11.89 | +42.62% |
Total Operating Expense | 170.67 | 164.16 | +3.97% | 144.98 | +17.72% |
Operating Income | 87.05 | 66.53 | +30.84% | 86.07 | +1.14% |
Net Income Before Taxes | 99.5 | 83.09 | +19.75% | 105.41 | -5.61% |
Net Income | 82.21 | 60.77 | +35.28% | 79.56 | +3.33% |
Diluted Normalized EPS | 3.21 | 2.39 | +34.31% | 3.13 | +2.56% |
Catch all the Business News , Corporate news , Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.